J
Jifeng Feng
Researcher at Nanjing Medical University
Publications - 84
Citations - 10806
Jifeng Feng is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 25 publications receiving 8891 citations. Previous affiliations of Jifeng Feng include Harbin Medical University & New Generation University College.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
Taroh Satoh,Rui-Hua Xu,Hyun Cheol Chung,Guo-ping Sun,Toshihiko Doi,Jianming Xu,Akihito Tsuji,Yasushi Omuro,Jin Li,Jinwan Wang,Hiroto Miwa,Shukui Qin,Ik-Joo Chung,Kun-Huei Yeh,Jifeng Feng,Akihira Mukaiyama,Mikiro Kobayashi,Atsushi Ohtsu,Yung-Jue Bang +18 more
TL;DR: Lapatinib plus paclitaxel demonstrated activity in the second-line treatment of patients with HER2 FISH-positive IHC3+ advanced gastric cancer but did not significantly improve OS in the intent-to-treat population.
Journal ArticleDOI
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi,Li Zhang,Xiaoqing Liu,Caicun Zhou,Shucai Zhang,Dong Wang,Qiang Li,Shukui Qin,Chunhong Hu,Yiping Zhang,Jianhua Chen,Ying Cheng,Jifeng Feng,Helong Zhang,Yong Song,Yi-Long Wu,Nong Xu,Jianying Zhou,Rongcheng Luo,Chunxue Bai,Ye-ning Jin,Wenchao Liu,Zhaohui Wei,Fenlai Tan,Yinxiang Wang,Lieming Ding,Hong Dai,Shunchang Jiao,Jie Wang,Li Liang,Weimin Zhang,Yan Sun +31 more
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Xiaoqing Liu,Yunzhong Zhu,Shun Lu,Jifeng Feng,Jianxing He,Baohui Han,Jie Wang,Guo-Liang Jiang,Chunhong Hu,Hao Zhang,Gang Cheng,Xiangqun Song,You Lu,Hongming Pan,Wenjuan Zheng,Anny-Yue Yin +18 more
TL;DR: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC.